Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Cat. No. : CSC-BS0006
Host Cell : CHO-K1 Size : >1x106 frozen cells/vial
| Cat. No. | CSC-BS0006 |
| Description | This cell line is engineered to stably produce Adalimumab which is a monoclonal antibody against human TNF. |
| Target Gene | Adalimumab |
| Host Cell | CHO-K1 |
| Host Cell Species | Cricetulus griseus (Chinese hamster) |
| Applications |
1. Biosimilar Development 2. Large-Scale Biomanufacturing 3. Preclinical Research 4. Drug Development and Testing |
| Size | >1x106 frozen cells/vial |
| Stability | Validated for at least 10 passages |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Growth Conditions | 37° C, 5% CO2 |
| Storage | Liquid nitrogen |
| Shipping | Dry ice |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
A: Adalimumab is a disease-modifying antirheumatic drug (DMARD) and monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNFα).
A: Adalimumab works by selectively binding to a protein called tumor necrosis factor-alpha (TNF-α). By binding to TNF-α, adalimumab inhibits its activity and reduces inflammation.
A: Pembrolizumab has shown promising results in treating many types of cancer, including melanoma, non-small cell lung cancer, and bladder cancer.
A: Yes. Adalimumab is a specific inhibitor of TNF-α, and does not affect other cytokines or immune cells. This makes it a targeted therapy with fewer side effects compared to non-specific immunosuppressive drugs that affect multiple pathways.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Great! To produce a therapeutic dose of Adalimumab, a stable cell line is needed.
The adalimumab stable cells are grown in suspension culture, which not only simplifies the purification process but also reduces the risk of contamination. I recommend it.
The stable cell line that produces functional pembrolizumab using CHO-K1 cells is a significant step forward in the fight against cancer. This helps a lot with my project.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.